Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A genomic study has uncovered molecular changes in patient tumors that may lead to dramatic and long-lasting responses to cancer therapy
First-line treatment with immunotherapy and a chemotherapy regimen extended progression-free survival by 35%.
Black men with breast cancer were more likely to be diagnosed at a later stage.
Longer delays were associated with worsening risk of death.
An antibody-drug conjugate could be a step toward selective treatment for neuroendocrine prostate cancer.
Areas with lower population density have not seen the same slowdown as urban areas.
Antibody-drug conjugates are targeted agents that package cancer drugs for special delivery to tumor cells.
While disease progression was higher in Black men, their rates of metastasis and mortality were similar to those of white men.
Requiring sobriety prior to treatment and curtailing harm reduction hinder efforts to eliminate hep C.
Enrichment of the lungs with oral commensal microbes is associated with negative effects in patients with lung cancer.
Among patients with high tumor PD-L1 expression, Libtayo lowered mortality by 43%.
Patients whose surgery was performed by a very skilled surgeon saw their risk of death decrease by 70% over five years.
Adagrasib targets a specific cancer-causing mutation, while VS-6766 interferes with multiple steps in a cell growth signaling pathway.
There’s a gender gap too. Doctors are more likely to discuss potential problems with men than with women.
Tumors with large numbers of genetic mutations may be especially susceptible to treatment with immunotherapy.
Developing treatments for fatty liver disease has proved challenging, and there are currently no approved medications.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.